Navigation Links
Cancer Cure Coalition Proposes Major Changes at the FDA
Date:2/21/2008

PALMS BEACH GARDENS, Fla., Feb. 21 /PRNewswire/ -- Flawed policies and bad decisions at the FDA have contributed to an escalation of the cost of clinical trials which now take an average of one billion dollars and require 10 years for approval. This has delayed and even prevented the availability of many promising treatment options, resulting in increased death and suffering for patients and greatly increasing the cost of medical treatment in the United States.

It's time to reform the FDA. It is failing in its mission and greatly harming the United States.

The FDA itself has acknowledged that it cannot do the job given to it by Congress and that it is failing in its mission. In a November 2007 report entitled "FDA Science and Mission at Risk," prepared for the FDA by its own subcommittee on Science and Technology, it states:

"The FDA cannot fulfill its mission because:

1.2.1) Its scientific base has eroded and its scientific organizational structure is weak.

1.2.2) Its scientific workforce does not have sufficient capacity and capability.

1.2.3) Its information technology (IT) infrastructure is inadequate."

It further states that "the lack of new science capability/capacity places the FDA mission at risk for those many products at the leading edge of innovation."

Proposals have been made by many that substantial additional funding be given to the FDA. There has even been a foundation, A Coalition for a Stronger FDA, formed to achieve this end. But as Dr. Henry I. Miller of the Hoover Institution pointed out in his book "To America's Health / A Proposal to Reform the Food and Drug Administration," and also in a letter to The New York Times published on February 10, 2008, additional resources alone are not enough. He stated, "the agency's most significant problems are mismanagement and a culture that is excessively risk-averse. Repeatedly accused (unjustly) of not being sufficiently concerned about drug safety, regulators keep raising the bar for approval, especially for innovative, high-tech products."

We at the Cancer Cure Coalition agree with Dr. Miller that "What the FDA needs is competent management, discipline in the ranks, more effective risk- benefit balancing, a commitment to permitting patients to assume more responsibility for the risk of medicines, and the banishment of politics from regulatory decisions and policy."

We think that reform is needed as soon as possible, and we propose the following steps be taken:

1. Substantial additional funding should be given to the FDA to help it fulfill the increase in duties placed upon it by the Congress.

2. The "Food" division should be separated from the "Drug" division. Insuring the safety of food for the United States is an enormous responsibility and would be best performed by an agency dedicated to that purpose.

3. A special study should be made by an independent organization to make sure that the FDA has competent management. Those managers who are incompetent should be replaced. In the "Drug" division, management is needed that will recognize the needs of the patients and that will apply effective risk-benefit balancing.

4. Consideration should be given to using certified non-governmental agencies to perform the oversight of drug testing and the review of new drug applications. This would reduce cost while improving the quality of the review process.

Unless we move for reform now, the FDA will continue to harm the interests of patients, our health industry and the economy of the United States.

Contact:

Charles A. Reinwald, Chairman

Charles Reinwald, Jr., President

Cancer Cure Coalition

561-747-2174

E-mail: cancercurecoal@aol.com

http://www.cancercurecoalition.org

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Cancer Cure Coalition
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
3. Diagnostic Center for Disease: Prostate Biopsy Spreads Prostate Cancer Cells
4. Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
5. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
8. Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint
9. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
10. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
11. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb. 27, 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... Craig , M.D., Ph.D., as President and Chief Executive Officer ... 20, 2017. Dr. Craig succeeds Richard Love , interim ... company,s Board of Directors.  Dr. Craig has over 20 years ... the US and Europe . ...
(Date:2/27/2017)... N.J. and PETACH TIKVAH, Israel ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... appointments of June S. Almenoff , M.D., Ph.D., ... to its Board of Directors.  "Dr. ... executives whose appointments come at an exciting time for ...
(Date:2/27/2017)... , Feb 27, 2017 Period October – December ... Operating result amounted to SEK -16.4 (-6.4) million ... per share (-0.22) before and after dilution Cash flow from ... ... to SEK 0.4 (0.4) million Operating result amounted to SEK ...
Breaking Medicine Technology:
(Date:2/27/2017)... , ... February 26, 2017 , ... Miro is the ... sound and video system brings songs, movies, TV shows and much more apps for ... clear, high-definition sound. An immersive view of 1280 x 720 provides crisp images with ...
(Date:2/27/2017)... ... 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International ... the Center for Disease Control ( CDC ) and Infectious Diseases Society of America ... M.D. has compiled into a single volume a compelling argument that the disease does ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail electric ... Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , Discount ... 800 customers and 2,250 RCEs at the time of acquisition. In the three ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is ... team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
Breaking Medicine News(10 mins):